Residual disease activity in cystic fibrosis lung disease: implications for clinical management and research.
This review proposes RDA as a conceptual framework for identifying ongoing, potentially modifiable disease processes in people receiving CFTR modulators and considers the implications of RDA for clinical research by identifying key evidence gaps and outlining a stepwise pathway for its definition and validation.